Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that BRAF p.V600E status confers therapeutic sensitivity to Dabrafenib, Trametinib in patients with Differentiated Thyroid Gland Carcinoma.
The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with locally advanced or metastatic differentiated thyroid cancer with a BRAF V600E mutation, refactory to or not eligible for radioactive iodine (RAI) who have progressed during or after prior systemic therapy.
This statement is based on a regulatory approval from the European Medicines Agency:
Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with locally advanced or metastatic differentiated thyroid cancer with a BRAF V600E mutation, refactory to or not eligible for radioactive iodine (RAI) who have progressed during or after prior systemic therapy.